The French-based company reported Q4 revenue of €58.6 million, marking a 2.6% increase year-on-year (YoY) on a reported basis, and a marginal decline of 0.4% on a like-for-like (l-f-l) basis. This ...

15% Over 2023 Results and Exceed Prior Product Revenue Guidance 2025 Product Revenues Expected to be Between $194-$200 million, Reflecting 8%-11% Growth Year-Over-Year CONCORD, Calif., January 13 ...

Product marketing and sales enablement teams share an ultimate goal: to help sales teams sell more. Each team has an important role in driving revenue. Product Marketing focuses on developing content ...

Automobile retail sales in the country grew 6.6 per cent year-on-year (Y-o-Y) in January, marking a “moderately positive” ...

Revenue, often colloquially referred to as sales, is the lifeblood of every business. It represents the total income generated by a company through its primary business activities. This financial ...

Murphy USA Inc. (NYSE:MUSA), a $10.02 billion market cap fuel retailer, reported its earnings for the fourth quarter of 2024, ...

TCBI's Q4 2024 results were disappointing overall, with declining net interest margin, slowed loan growth, and deposits far ...

LyondellBasell is in solid financial health. Management reported a net debt/adjusted EBITDA ratio of 1.8 times as of Dec. 31, 2024. We expect the leverage ratio will remain healthy over time as the ...

Preliminary ELEVIDYS net product revenue totaled $384.2 million for the fourth quarter, exceeding guidance by over $60 million, and $820.8 million for full-year 2024 – Preliminary RNA-based PMO ...

This allows Dow to manufacture at a significant cost advantage to marginal cost producers that rely on higher-cost crude oil-based feedstocks to make the same products. Dow’s commodity chemicals are ...

Investopedia / Julie Bang The term cost of revenue refers to the total cost of manufacturing and delivering a product or service to consumers. Cost of revenue information is found in a company's ...

(NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31 ...